💬 For the first issue of Insights by Servier, we had the opportunity to interview Mathieu Lamiaux, Managing Director and Senior Partner at Boston Consulting Group (BCG), and Jerome Klein, Head of Corporate Strategy at Servier, about the opportunities and challenges of being a mid-size company in the pharmaceutical sector. 📣 Listen to Mathieu Lamiaux talk about the role of mid-size pharmaceutical companies and how that can bring its own rewards. Read the full interview with Mathieu Lamiaux and Jerome Klein on the opportunities and challenges for mid-size pharma in the latest issue of Insights by Servier 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #MidSizePharma
Servier’s Post
More Relevant Posts
-
By 2027, the healthcare GenAI market is expected to grow from $1 billion to $22 billion, an 85% annual growth rate. 90% of pharmaceutical companies are already actively developing GenAI capabilities, as revealed in a recent study by BCG and Microsoft. This study, involving leading digital executives from the world's largest pharmaceutical firms, was unveiled at the J.P. Morgan Healthcare Conference. For pharmaceutical companies, effectively utilizing GenAI involves three key priorities: potential, platform, and partnership. 💊 Learn more about these three elements and discover how to strategically embrace and implement this groundbreaking technology in biopharma. https://on.bcg.com/3O06iP2 #jpm2024 #BCGonAI
-
-
Check out this interview and article from industry experts Diluks De Silva and Geoff Micks at PMWS 2023 about talent acquisition in the pharmaceutical industry! 🌟 Stay ahead with the latest insights and strategies. https://lnkd.in/eYU88HUb #PharmaTalent #InnovativeRecruitment #PMWS2023 🏥💼
-
-
By 2027, the healthcare GenAI market is expected to grow from $1 billion to $22 billion, an 85% annual growth rate. 90% of pharmaceutical companies are already actively developing GenAI capabilities, as revealed in a recent study by BCG and Microsoft. This study, involving leading digital executives from the world's largest pharmaceutical firms, was unveiled at the J.P. Morgan Healthcare Conference. For pharmaceutical companies, effectively utilizing GenAI involves three key priorities: potential, platform, and partnership. 💊 Learn more about these three elements and discover how to strategically embrace and implement this groundbreaking technology in biopharma. https://on.bcg.com/3O06iP2 #jpm2024 #BCGonAI
-
-
🌟 Did you catch the thought-provoking panel discussion on access opportunities for #rarediseases in and out of Europe yesterday? 🤔 The discussion, led by representatives from Charles River Associates, delved into the evolving European access landscape and its potential influence on future orphan drug launch strategies. Additionally, the session provided valuable insights by comparing the opportunities and challenges within Europe to those in other promising markets for pharmaceutical manufacturers. 🌍 💡 Our 𝐃𝐚𝐲 𝟐 𝐒𝐮𝐦𝐦𝐚𝐫𝐲 𝐫𝐞𝐩𝐨𝐫𝐭 brings you all the highlights, including this discussion and more from the Access & Pricing and Real World Evidence tracks. 𝐃𝐢𝐯𝐞 𝐢𝐧 ➡ https://lnkd.in/eruynjKe #HealthcareInnovation #MarketAccess #RareDiseases World Orphan Drug Congress Europe #Healthcare #orphandrugs
-
Green Electricity can be used in all sorts of ways in a Net Zero world, whether that be to decarbonise Electricity use, Heating or Transport - both residential and industrial. The real question will be about where the most value will be for renewables companies to use and sell that power. I'm looking forward to speaking at the Future in Pharmaceuticals Ireland 2024 and the Energy in Ireland Transport Forum conferences, both in February, on the solutions Bord na Móna is developing in each of these spaces.
Future in Pharmaceuticals Ireland 2024 - Aviva Stadium, Dublin - 27th February... Hear from: Boston Scientific, MSD (Ballydine), AbbVie, Hovione Pharmaceuticals, Johnson & Johnson and many more..... Continuous improvement of the Irish Pharmaceutical Manufacturing's Sustainability profile is the core theme of Future in Pharmaceuticals Ireland networking event. For 8-years this symposium has provided a peer to peer environment of open conversation, learning and understanding of the challenges and opportunities that are available through Scope 1, 2 & 3 initiatives. Register to attend today at: https://lnkd.in/eebRJMNz
-
-
📢 Delve into the Insights of Bulgaria's Pharmaceutical Industry and Media Landscape 💊📰 Our latest report on the pharmaceutical industry in Bulgaria and its intricate media landscape provides a comprehensive look into the critical findings shaping this dynamic sector. Join us as we unveil the essential discoveries that can impact the future of healthcare and media trends and get all the details from the full report here 👉 https://lnkd.in/dgWQCJr2 #pharmaindustry #mediamonitoring #socialmedialistening #bigdata #perceptica
-
📢 On May 15, #ProximaResearch became a partner of the 29th Kazakhstan International Healthcare Exhibition #KIHE2024 💊🎤 Ekaterina Markova, Director of Proxima Research Kazakhstan, participated in a panel discussion on the topic “Analysis and development prospects of the pharmaceutical market”, where she presented analytics of the pharmaceutical market #MarketAudit of medicines for the 1st quarter of 2024 Read more about the event in the article: https://cutt.ly/MerpeyW3 ❗If you would like to see our presentation, please leave a “+” in the comments 📨
-
-
14-15 March – Barcelona, Spain Our final session at Clinigen Insights sees Claudia Martínez, Head of Research at the Access to Medicines Foundation, discuss the evolving landscape of access strategy integration within pharmaceutical companies' new product development. Gain invaluable insights into our industry's concerted efforts to enhance access in Low- and Middle-Income Countries (LMIC). The session will be followed by a panel discussion and Q&A featuring experts from our Clinigen Regulatory, Commercial, and Consulting teams to delve into the nuances of the transition from Managed Access program to commercial strategy and explore novel approaches to non-launch market access for emerging treatments. Find out more and RSVP (while places are still available): https://bit.ly/3GF1SJm #managedaccess #expandedaccess #earlyaccess #realworlddata
-
-
🚀 New drug approvals June 2024 June FDA and EMA approvals for new drugs and vaccines are here. Recent approvals: 👉 FDA: Rytelo of Geron Corporation, Iqirvo of Ipsen, Sofdra of Botanixs, Piasky of Genentech, Ohtuvayre of VERON PHARMA Vertriebs GmbH 👉 EMA: Balversa of Johnson & Johnson, Eurneffy of ARS Pharmaceuticals, Inc., MResvia of Moderna, Ordspono of Regeneron, Piasky of Roche, Winrevair of Merck This month, we've highlighted five standout drugs to better understand how they compare with available treatments: Rytelo, Ohtuvayre, Iqirvo, Winrevair, and mResvia. Interested in more information on future launches? Sign up to be the first to receive the updates. https://lnkd.in/g3Rr-_Js #druglaunch #pharma #pharmaceuticals #biotech #fda #ema #drugapprovals #competitiveintelligence #insights #launchstrategy
-
In the latest episode of #Biopharma R&D Practitioner Voices, Marc P. Philipp and Pia K. are joined by Michael May, medical director Germany at Bristol Myers Squibb, and Matthias Meergans, general manager for research and development at Verband Forschender Arzneimittelhersteller e.V. (VFA) Germany, to discuss the actions Germany can take to attract more #research and development in the #pharmaceutical industry. Watch the full interview here: https://bit.ly/3U3hA90
